New Models of PENTAX Medical i20c Video Endoscope Series Obtain CE Marks
PENTAX Medical, a division of HOYA Group, have obtained CE marks for new models of PENTAX Medical i20c Video Endoscope Series – PENTAX Medical Video Colonoscope EC34-i20c, PENTAX Medical Video Upper GI Scope EG27-i20c and R/L Knob Adaptor OE-B17. In…
Alexandria Real Estate Equities, Inc. Continues Its Distinctive, Steadfast and Positive Impact on the Widespread and Complex Mental Health Crisis
Alexandria Real Estate Equities, Inc. (NYSE: ARE), the first, preeminent, longest-tenured and pioneering owner, operator and developer of collaborative life science mega campuses in AAA innovation cluster locations, continues to make a distinctive, steadfast and positive impact on the widespread and…
Reese Pharmaceutical Launches New At-Home Colon Cancer Screening Test
Reese Pharmaceutical is expanding its over-the-counter (OTC) diagnostic portfolio with the launch of ColoTest®, an at-home Fecal Immunochemical Test (FIT) that identifies the presence of hidden blood in the stool in support of the early detection of colon cancer or gastrointestinal disorders…
M3 launches Doctors.net.uk: ‘Pathway’ to Support International Medical Graduates Relocating to the UK’
M3 (EU) has announced the international launch of ‘Doctors.net.uk: Pathway’, the latest addition to Doctors.net.uk, the UK’s leading online community of more than 250,000 GMC-registered doctors. M3 (EU) recently unveiled the new, exclusive online platform, which is designed to provide…
SK bioscience Receives WHO Prequalification for Typhoid Conjugate Vaccine
SK bioscience, a global innovative vaccine and biotech company committed to promoting human health from prevention to cure, announced today that the company has obtained prequalification (PQ) certification from the World Health Organization (WHO) for its typhoid conjugate vaccine (TCV),…
Zealand Pharma announces Boehringer Ingelheim survodutide Phase 2 trial shows 83% of adults treated achieved groundbreaking results in liver disease due to MASH, with significant improvements in fibrosis
Zealand Pharma A/S (Nasdaq: ZEAL) today announced that Boehringer Ingelheim has reported that up to 83.0% of adults treated with survodutide (BI 456906) achieved a statistically significant improvement of metabolic dysfunction-associated steatohepatitis (MASH) versus placebo (18.2%) in a Phase 2…
PCM Trials Acquires EmVenio Research to Create the Most Patient-Centric Model for Hybrid and Decentralized Clinical Trials
Denver-based PCM Trials, the largest independent mobile research nurse visit provider for decentralized clinical trials (DCTs), today announced the acquisition of EmVenio Research based in Durham, North Carolina. EmVenio is the largest provider of community-based clinical trial sites served with mobile research units. The…
China Medical University Hospital’s Breakthrough: Leg Salvage Against Deadly Arterial Disease. Amputation and Death Rates Plunge from 30% to Below 3%
In winter, cardiovascular diseases are more prevalent, which significantly increase the likelihood of arterial blockage. In addition to increasing the possibility of accompanying myocardial infarction or stroke, seniors should be especially cautious about Peripheral Arterial Occlusive Disease (PAOD). In mild…
The New England Journal of Medicine Publishes Positive Phase 3 RESPONSE Data of CymaBay’s Seladelpar in Primary Biliary Cholangitis
CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a biopharmaceutical company focused on innovative therapies for patients with liver and other chronic diseases, today announced that The New England Journal of Medicine (NEJM) has published detailed results from the RESPONSE Phase 3 trial evaluating seladelpar, an…
Servier Receives Regulatory Filing Acceptances from FDA and EMA for Vorasidenib in the Treatment of IDH-Mutant Diffuse Glioma
Servier, a global leader in oncology focused on delivering meaningful therapeutic progress for the patients it serves, today announced the FDA filing acceptance and priority review for a New Drug Application (NDA) for vorasidenib, as well as the EMA granting…
